Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1619 1648 1671
This examiner grants 73% of resolved cases
Shanon A. Foley is a patent examiner in Tech Center 1600 and Art Unit 1600. He has reached a resolution in 985 cases. The data shows an allowance rate of 73.3 percent for these applications. This percentage indicates that nearly three-quarters of the cases assigned to him result in a patent grant. Practitioners can use this 73.3 percent rate to gauge the general likelihood of success for applications in this technology area.
Interviews appear to be an effective strategy for this examiner, as shown by an interview lift of 18.1 percent. This metric indicates that direct communication is associated with a significant increase in the probability of allowance. An interview lift of 18.1 percent suggests that verbal negotiation is a productive tool for overcoming rejections and clarifying claim language. Practitioners should consider scheduling an interview to leverage this benefit during the examination process.
The median days to allowance for successful cases is 1026. This duration represents the middle value of the time taken from filing to the issuance of a patent. A median of 1026 days provides a specific timeline for applicants to consider when managing their patent portfolios. These metrics are based on 985 resolved cases, offering a robust and data-grounded perspective on the examiner's historical prosecution patterns.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18884822 | COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION | Non-Final OA | The University of North Carolina at Chapel Hill |
| 18173535 | BROADLY PROTECTIVE INFLUENZA B VIRUS VACCINES | Non-Final OA | Wisconsin Alumni Research Foundation |
| 18572268 | IN-SITU AND REAL-TIME GENERATION AND ADMINISTRATION OF VIRAL VACCINES USING UV LIGHT INACTIVATION | Non-Final OA | SIGNIFY HOLDING B.V. |
| 18780122 | METHODS AND MATERIALS FOR PRODUCING RECOMBINANT VIRUSES IN EUKARYOTIC MICROALGAE | Non-Final OA | The Research Institute at Nationwide Children's Hospital |
| 17914735 | REVERSE GENETIC SYSTEM FOR SARS-COV-2 | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18699159 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | Non-Final OA | Pfizer Inc. |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | Final Rejection | PFIZER INC. |
| 18003056 | COMBINATION PORCINE VACCINE | Non-Final OA | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. |
| 18559263 | COMPOSITIONS AND METHODS FOR SARS CoV-2 RNA DETECTION | Non-Final OA | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 18977008 | VACCINES COMPRISING METHANOBREVIBACTER GOTTSCHALKII | Non-Final OA | Arkea Bio Corp. |
| 18700677 | COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES | Non-Final OA | Duke University |
| 18523331 | LARGE-SCALE FLAVIVIRAL VACCINE PRODUCTION AND MANUFACTURE | Non-Final OA | Takeda Vaccines, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy